Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL38 Near-Infrared Imaging in Folate Receptor Positive Lung Nodules
2017-003560-13Phase 2Completed
- Sponsor
- On Target Laboratories
- Start
- Oct 2017
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pafolacianine in bronchial carcinoma and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by On Target Laboratories. Primary endpoints: Sensitivity of OTL38 for malignancy detection during near-infrared imaging and False positive rate of OTL38 for malignancy detection during near-infrared imaging. Started Oct 2017; status: completed.
02
Drugs
pafolacianine
03
Conditions
bronchial carcinomaNon-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2017-003560-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003560-13.